Clinical Trial Update: Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of BMS-986205 and nivolumab in patients with endometrial adenocarcinoma or endometrial carcinosarcoma that h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Carcinosarcoma

Drugs mentioned

• BMS-986205 (BMS-986205)
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Endometrial Adenocarcinoma, Endometrial Carcinosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING